Minimal residual disease in acute myelogenous leukemia.

Abstract excerpt

Treatment of acute myelogenous leukemia (AML) over the past four decades remains mostly unchanged and the prognosis for the majority of patients remains poor. Most of the significant advances that have been observed are in defining cytogenetic abnormalities, as well as the genetic and epigenetic profiles of AML patients. While new cytogenetic and genetic aberrations such as the FLT3-ITD and NPM1 mutations are...

Topics

Join the communities discussing this publication.

• Flow Cytometry
• fms-Like Tyrosine Kinase 3
• High-Throughput Nucleotide Sequencing
• Leukemia, Myeloid, Acute
• Neoplasm, Residual